Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (326)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Tiragolumab	TIGIT Inhibitor	Solid Tumour
Molecule Tiragolumab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
EOS-448 (Belrestotug)	TIGIT Inhibitor	Solid Tumour
Molecule EOS-448 (Belrestotug) Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Bozitinib	MET Inhibitor	Solid Tumour
Molecule Bozitinib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Glumetinib	MET Inhibitor	Solid Tumour
Molecule Glumetinib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Elzovantinib	MET Inhibitor	Solid Tumour
Molecule Elzovantinib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Bavdegalutamide	Androgen Receptor Degrader (PROTAC)	Solid Tumour (Prostate)
Molecule Bavdegalutamide Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
ARV-110 (Bavdegalutamide)	Androgen Receptor Degrader (PROTAC)	Solid Tumour (Prostate)
Molecule ARV-110 (Bavdegalutamide) Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
ARV-471 (Vepdegestrant)	Androgen Receptor Degrader (PROTAC)	Solid Tumour (Prostate)
Molecule ARV-471 (Vepdegestrant) Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
CC-94676	Androgen Receptor Degrader (PROTAC)	Solid Tumour (Prostate)
Molecule CC-94676 Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
Masofaniten	Androgen Receptor Degrader (PROTAC)	Solid Tumour (Prostate)
Molecule Masofaniten Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
Tarlatamab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Tarlatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Ivonescimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

Tiragolumab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
EOS-448 (Belrestotug) Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Bozitinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Glumetinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Elzovantinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism MET Inhibitor
Bavdegalutamide Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
ARV-110 (Bavdegalutamide) Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
ARV-471 (Vepdegestrant) Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
CC-94676 Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
Masofaniten Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
Tarlatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

‹ 1 … 23 24 25 26 27 28 ›

Product Range

Company

Global Network

Products

Tiragolumab

EOS-448 (Belrestotug)

Bozitinib

Glumetinib

Elzovantinib

Bavdegalutamide

ARV-110 (Bavdegalutamide)

ARV-471 (Vepdegestrant)

CC-94676

Masofaniten

Tarlatamab

Ivonescimab

Tiragolumab

EOS-448 (Belrestotug)

Bozitinib

Glumetinib

Elzovantinib

Bavdegalutamide

ARV-110 (Bavdegalutamide)

ARV-471 (Vepdegestrant)

CC-94676

Masofaniten

Tarlatamab

Ivonescimab